# Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

> **NCT05238649** · PHASE2 · UNKNOWN · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 150 (actual)

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
- **BIOLOGICAL:** Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg
- **BIOLOGICAL:** SARS-Cov-2 Vaccine Inactivated

## Key facts

- **NCT ID:** NCT05238649
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-10
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-01-28
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238649, "Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05238649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*